The promising potential of PARP inhibitors in ovarian cancer
The success of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Should all platinum sensitive patients recieve PARP inhibitors?
Niraparib as maintenance for platinum-sensitive ovarian cancer - results from ENGOT-OV16/NOVA trial
Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer